Podcasts about breakthroughs

Join The Struggle's Patreon community to get 100+ hours of Bonus Episodes, Pro Clinics, Uncut Videos, and Submit Questions for Future Guests. FREE TRIAL available!  https://www.patreon.com/thestruggleclimbingshow - Elite climber, Tim Emmett, explores: The moments surrounding the send of Era Vella (9a) Dealing with relentless failure Overcoming countless injuries and setbacks 8 years of effort and commitment Being his fittest and strongest at age 51 The invisible costs of taking on a huge project  The training breakthrough prescribed by Neil Gresham Having a total emotional breakdown  The diet change that changed everything Letting go of the outcome  Skills over strength Here's Tim's emotional video just after sending the proj: https://www.instagram.com/p/DRH5YN4CEa0/ - BIG THANKS TO THE AMAZING SPONSORS OF THE STRUGGLE WHO LOVE ROCK CLIMBING AS MUCH AS YOU DO: Kilter: Award winning, adjustable, light-up boards. I'm training on the Homewall Full Ride, and if you're psyched to join me then use code STRUGGLE at checkout when you build your board, and you'll score up to $1000 off plus a free gift pack let's goooo! PhysiVantage: the official climbing-nutrition sponsor of The Struggle. Train harder, recover faster, and feel better than ever. I love all their stuff! Use code STRUGGLE15 at checkout for 15% off your full-priced nutrition order. Rúngne: Soft threads and high performing chalk! Use Code STRUGGLE for 10% Off Bags, Buckets, Chalk & Apparel from Rúngne! Rungne.com   And check out ALL the show's awesome sponsors and exclusive deals at thestruggleclimbingshow.com/deals   - Shoutout to Matt Waltereese for being a Victory Whip supporter on Patreon! So mega. - Here are some AI generated show notes (hopefully the robots got it right) 00:00 Introduction and Welcome 03:14 Interview with Tim Emmett Begins 04:01 Tim's Emotional Journey and Achievements 08:25 Challenges and Family Sacrifices 13:05 Mental and Physical Preparation 28:10 Training and Nutrition Insights 35:36 Injury and Diet Impact 36:09 Performance Eating vs. General Diet 39:13 Balancing Happiness and Discipline 40:51 Winter Climbing and Training Goals 42:38 PhysiVantage Sponsorship 44:07 The Struggle Patreon Community 45:38 Reflecting on Personal Climbing Achievements 47:09 The Journey to Climbing Success 01:02:19 Listener Questions and Final Thoughts - Follow along on Instagram @thestruggleclimbingshow and YouTube /@thestruggleclimbingshow - The Struggle is carbon-neutral in partnership with The Honnold Foundation, whose mission is to promote solar energy for a more equitable world. - This show is produced and hosted by Ryan Devlin, and edited by Glen Walker. The Struggle is a proud member of the Plug Tone Audio Collective, a diverse group of the best, most impactful podcasts in the outdoor industry. - The struggle makes us stronger! I hope your training and climbing are going great.  - And now here are some buzzwords to help the almighty algorithm get this show in front of people who love to climb: rock climbing, rock climber, climbing, climber, bouldering, sport climbing, gym climbing, how to rock climb, donuts are amazing. Okay, whew, that's done. But hey, if you're a human that's actually reading this, and if you love this show (and love to climb) would you think about sharing this episode with a climber friend of yours? And shout it out on your socials? I'll send you a sticker for doing it. Just shoot me a message on IG – thanks so much!   

Advancing longevity research is about honoring the value of life—and translating that respect into evidence-based prevention. If healthcare is judged by life expectancy + quality of life, longevity medicine may be one of the most meaningful metrics we can pursue: extending health span through early detection, validated biomarkers, and interventions that scale.This unforgettable Expert Panel from the 4th annual Medical Innovation Olympics (#MIO2025) convened all-star global leaders in Longevity and Preventive Medicine who separated hype from reality and outlined what it will take to bring longevity into mainstream care - rigorously, ethically, and accessibly.Topics include: breakthroughs (including epigenetic approaches pointing toward functional restoration of eyesight), biomarkers/endpoints as the “keystone” for faster trials, the TAME (Targeting Aging with Metformin) concept, and the role of standards, education, trust, and shared responsibility—keeping dignity central.Panelists:Dr. David Barzilai (Harvard Medical School; Geneva College of Longevity Science, GCLS) • Dr. Dominik Thor (President, GCLS) • Dr. Mishkat Shehata (Emirates Lifestyle & Longevity Medicine Society) • Keith Comito (Lifespan Research Institute) • Dr. Uma Senthilkumar (Three Five Revive)

Ps. Samuel contiunes of Bursting forth series

Ready for a reframe that actually changes how you lead? We sit down with transformational coach Dan Tocchini to unpack why conflict isn't a detour from progress but the most reliable road to it. From the first moment you commit to a bold outcome, resistance appears. Dan shows how to meet that resistance with clear aims, better questions, and conversations that create alignment instead of drama.We dive into the mindset shift that turns breakdowns into breakthroughs. Rather than fall into blame, shame, or chasing credit, Dan walks us through a simple operating system: accept the results your system produces, then ask what's working, what's not, and what's missing for the future you're committed to. We also explore how to argue well. You'll learn to slow down, surface premises, avoid logical traps, and take the other person's side so well they nod. That's how teams get smarter fast.When defensiveness spikes, Dan offers a disarming move: ask what could be true in what they're saying. Pair that with honest speech—naming what's real for you now—and you speed up the path to truth and trust. We round out with The Change Imperative, Dan's practical framework for leading transitions: identify natural influencers, win the fence-sitters, engage the levelers, and expect turbulence before lift. If you want meetings with less heat and more light, this one's a playbook.Grab Dan's free ebook “The Change Imperative” at takenewground.com, then tell us your biggest takeaway. If this conversation helped, follow the show, share it with a friend, and leave a quick review so more leaders can turn conflict into momentum.Hi This is Brad Weisman - Click Here to Send Me a Text Message ---Welcome to The Brad Weisman Show, where we dive into the world of real estate, real life, and everything in between with your host, Brad Weisman!

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some fascinating updates that are shaping the future of medicine and healthcare.Let's start with a groundbreaking development in cancer treatment. Researchers have announced significant progress in a novel therapy targeting a specific mutation often found in non-small cell lung cancer. This mutation, known as EGFR exon 20 insertion, has historically been resistant to standard treatments. The new therapy employs a targeted approach that precisely inhibits the mutant protein while sparing normal cells. Early-phase clinical trials have shown promising results, with substantial tumor shrinkage observed in participants. This could potentially redefine treatment protocols for patients who previously had limited options and improve their overall survival rates. As the study progresses into later phases, the industry is watching closely to see if these initial successes translate into long-term benefits.In another significant development, we're seeing advancements in gene therapy for inherited retinal diseases. A recent study has highlighted a novel gene-editing technique that promises to restore vision in patients with certain genetic forms of blindness. By utilizing CRISPR-Cas9 technology, scientists have been able to directly correct mutations in retinal cells. The preclinical models have shown restored function and improved visual responses, paving the way for human trials. This breakthrough is not just a beacon of hope for those affected by genetic blindness but also underscores the transformative potential of gene-editing technologies in treating complex diseases.Moving on to regulatory news, there's an update on new drug approvals that could have widespread implications for public health. The FDA has recently approved a first-in-class drug for the treatment of severe migraines. This medication represents a novel mechanism of action by targeting the calcitonin gene-related peptide (CGRP) pathway, which plays a crucial role in migraine pathophysiology. Clinical trials indicated that it significantly reduces the frequency and severity of migraine attacks compared to existing treatments. For millions of sufferers worldwide, this approval offers a new avenue for relief and highlights the importance of continued innovation in chronic pain management.Shifting gears to vaccine development, there's exciting progress in the fight against infectious diseases. A new vaccine candidate for malaria has shown an unprecedented level of efficacy in trial settings. This vaccine utilizes a protein-based approach that targets multiple stages of the parasite's lifecycle, thereby enhancing its protective effects. Given malaria's devastating impact globally, particularly in sub-Saharan Africa, this development is being hailed as a potential game-changer in global health efforts. As further studies and real-world evaluations unfold, this vaccine could become a cornerstone tool in reducing malaria's burden.Now turning our attention to industry trends, there's growing momentum around personalized medicine and its integration into mainstream healthcare systems. Personalized medicine tailors treatment strategies to individual patient profiles based on genetic, environmental, and lifestyle factors. Recent advances in genomics and data analytics have accelerated this shift, allowing for more precise and effective interventions. For healthcare providers and pharmaceutical companies alike, this trend necessitates rethinking traditional drug development models and embracing collaborative approaches to harness big data effectively.Finally, let's look at an intriguing development in neurodegenerative disease research. Scientists are exploring a new class of drugs designed to target protein misfolding—an underlying cause of conditions Support the show

Hey, Heal Squad! Welcome to Part 2 of our conversation with Aliza Kelly… renowned celebrity astrologer, author, and host of Horoscope Weekly. This episode goes deeper, more intuitive, and a little more cosmic. Aliza shares her #1 manifestation tip that isn't about chasing titles or outcomes, but about creating expansion in your life.Maria also opens up in a big way, sharing Athena's birth story! Like what she learned about babies born en caul and why they're believed to have heightened intuitive or psychic abilities. What Athena has already said and sensed at just two years old will blow your mind! And then… Aliza drops her boldest predictions yet for 2026 and beyond. Are we nearing the end of social media as we know it? Could cancer cures once thought impossible actually arrive? And what's really changing beneath the surface of it all? If you're curious, open-minded, and ready to look ahead with clarity, this is a must-listen! HEALERS & HEAL-LINERS:  2026 Marks a Turning Point for Healing, Health & Medicine: 2026–2027 could usher in monumental medical breakthroughs, potentially even cures for diseases we once thought were untouchable, including cancer. Technology Will Advance, But Human Connection Will Be the Real Revolution: As Uranus moves into Gemini, technology (especially AI) will accelerate fast, but social media as we know it may lose its grip. News may become AI-generated, and digital spaces may feel increasingly disconnected leading to a hunger for authentic human connection.   HEAL SQUAD SOCIALS IG: https://www.instagram.com/healsquad/ TikTok: https://www.tiktok.com/@healsquadxmaria HEAL SQUAD RESOURCES: Heal Squad Website:https://www.healsquad.com/ Heal Squad x Patreon: https://www.patreon.com/HealSquad/membership Maria Menounos Website: https://www.mariamenounos.com My Curated Macy's Page: Shop My Macy's Storefront EMR-Tek Red Light: https://emr-tek.com/discount/Maria30 for 30% off Airbnb: https://www.airbnb.com/maria  Thrive Causemetics: https://thrivecausemetics.com/healsquad Get 20% OFF with this link!  Briotech: https://shopbriotech.com/ Use Code: HEALSQUAD for 20% off  GUEST RESOURCES: Aliza Kelly Instagram: https://www.instagram.com/alizakelly/?hl=en Aliza Kelly TikTok: https://www.tiktok.com/@alizakelly?lang=en Horoscope Weekly: Astrology with Aliza Kelly on YouTube: https://www.youtube.com/watch?v=C4XLXsZu5aU&list=PL68KtTdM9Bug4uhu9zKRRemKMlqUpMeES The Constellation Club, Aliza's virtual astrology & spirituality community: https://constellation-club.com/ ABOUT MARIA MENOUNOS: Emmy Award-winning journalist, TV personality, actress, 2x NYT best-selling author, former pro-wrestler and brain tumor survivor, Maria Menounos' passion is to see others heal and to get better in all areas of life. ABOUT HEAL SQUAD x MARIA MENOUNOS: A daily digital talk-show that brings you the world's leading healers, experts, and celebrities to share groundbreaking secrets and tips to getting better in all areas of life. DISCLAIMER: This Podcast and all related content (published or distributed by or on behalf of Maria Menounos or http://Mariamenounos.com and http://healsquad.com) is for informational purposes only and may include information that is general in nature and that is not specific to you. Any information or opinions provided by guest experts or hosts featured within website or on Company's Podcast are their own; not those of Maria Menounos or the Company. Accordingly, Maria Menounos and the Company cannot be responsible for any results or consequences or actions you may take based on such information or opinions. This podcast is presented for exploratory purposes only. Published content is not intended to be used for preventing, diagnosing, or treating a specific illness. If you have, or suspect you may have, a health-care emergency, please contact a qualified health care professional for treatment.

A Falun Dafa practitioner in Australia living in a remote area made breakthroughs in truth clarification efforts when she initiated a project to mail flyers about the persecution, which has reached thousands of residents. She also overcame attachments to entertainment and politics, which helped improved her focus during Fa study, and eliminate interference in her cultivation. This and other experience-sharing from the Minghui website.Original Articles:1. [Fahui] Cultivation Breakthroughs While Telling People About Falun Dafa2. [Fahui] My Realizations After I Began Practicing Falun Dafa3. I Realized the Harm of Complacency To provide feedback on this podcast, please email us at feedback@minghuiradio.org

Omari Richins, MPH of Public Health Careers podcast discusses the significant public health victories of 2025, highlighting the resilience and innovation of health professionals worldwide. Despite challenges like funding cuts and public skepticism, breakthroughs emerged, including the world's first pandemic agreement, advancements in HIV prevention, and new treatments for malaria and tuberculosis. These achievements underscore the importance of collaboration and innovation in public health.

There is still much to learn about Parkinson's disease (PD), and it remains an ongoing challenge for scientists and researchers. The Parkinson's Foundation recognizes the importance of supporting new and innovative ideas to advance research toward a cure.    Research takes time- from a conceptual idea to early laboratory work, with the hope of eventually progressing to clinical stages and, ultimately, a breakthrough. PD GENEration: Powered by the Parkinson's Foundation is a global research initiative that offers genetic testing and counseling to people with Parkinson's. The goal is to use the genetic data collected to accelerate current and future clinical trials aimed at developing better, more personalized treatments for Parkinson's.    In this episode, we speak with Connor Courtney, Associate Director of Research Programs at the Parkinson's Foundation. He takes a deep dive into how basic science lays the groundwork for future research and highlights the importance of supporting young scientists throughout their career in Parkinson's research. We later invite Maggie Caulfield, Director of Research Programs, who shares recent key insights from the PD GENEration study and discusses current challenges in Parkinson's research. Together, Maggie and Courtney emphasize the vital role individuals can play by learning more about and participating in research.   Follow and rate us on your favorite podcast platform to be notified when there's a new episode! Let us know what other topics you would like us to cover by visiting parkinson.org/feedback.

In this powerful conversation, Shauna Lynn Simon sits down with mindset coach and author Rusty Osborne to explore a counterintuitive truth many high-achieving entrepreneurs miss: the very thoughts you try to silence may be pointing to your next breakthrough. Rusty shares his own journey from building a business that looked successful on the outside to confronting the unseen mental blocks that quietly stalled his growth, and how that reckoning reshaped the way he now helps others lead with clarity and confidence.Listeners will gain a fresh lens on overwhelm, self-doubt, and imposter syndrome, learning why positive thinking alone often falls short and how working with negative self-talk can create real momentum. Through practical insights rooted in neuroscience, mindset work, and lived experience, this episode reveals how trust in yourself is built, how freedom expands when you stop resisting discomfort, and why sustainable success starts beneath the surface.If you're heading into a new season of leadership and want fewer mental roadblocks and more ease, this episode offers a grounded, actionable perspective worth sitting with - and sharing with someone who needs it.Timestamps:(00:02) - (07:15): Rusty Osborne explains why negative self-talk isn't something to eliminate, but a signal pointing directly to hidden mental blocks.(07:16) - (18:42): Shauna Lynn Simon and Rusty Osborne unpack the limits of “think positive” culture and why it often keeps entrepreneurs stuck in overwhelm.(18:43) - (32:10): Rusty Osborne shares his personal business collapse and the mindset shift that helped him rebuild with clarity, alignment, and ease.(32:11) - (47:55): A deep dive into imposter syndrome, money beliefs, and why fear of success quietly sabotages capable, high-performing women.(47:56) - (01:05:20): Rusty Osborne breaks down how subconscious rewiring builds self-trust, expands freedom, and creates sustainable leadership going into 2026.Resources:Book Your FREE Coaching Assessment Call with Shauna Lynn: https://www.aboutshaunalynn.com/coachmeLearn more about the show: AboutShaunaLynn.com/podcastRusty Osborne:Learn more about Rusty: https://rustyosborne.com/ Follow Rusty on Facebook: https://www.facebook.com/thecoachrusty Follow Rusty on Instagram: https://www.instagram.com/thecoachrusty Subscribe to Rusty on YouTube: https://www.youtube.com/@TheCoachRustyListeners of The Real Women Real Business Podcast get Rusty's book, The Power of Negative Thinking, plus bonuses for free at https://www.thepowerofnegativethinkingbook.com/shaunalynn (or purchase on Amazon here https://amzn.to/491ZL19)About Rusty Osborne:Rusty Osborne is the go-to mindset coach for entrepreneurs who need to get out of their own way. He's helped hundreds of business owners use their negative self-talk to ditch overwhelm and break through their biggest mental blocks. His book The Power of Negative Thinking is out now on Amazon!

Timeline Mitopure Gummies — The #1 Urolithin A supplement for energy and healthy aging, now in delicious strawberry gummies. Get 20% off at timeline.com/vanessa In today's episode, I'm continuing our Best of 2025 series with a powerful follow-up to Friday's episode. Instead of an interview, this is a curated masterclass pulling together the most important breakthroughs of 2025 in body recomposition, fat loss, and protein metabolism — especially for women navigating perimenopause and midlife metabolic change. You'll hear standout moments from conversations with Dr. Hannah Cabré, Dr. Arny Ferrando, and Dr. Mike Ormsbee, alongside a solo deep dive into one of the most exciting human randomized controlled trials published in 2025 on high-protein diets, accelerated belly-fat loss, and autophagy. Full Episode with Dr. Hannah Cabré Full Episode with Dr. Arny Ferrando Full Episode with Dr. Mike Ormsbee Full Episode on New Study on Protein Fasting Mimicking and Autophagy/Longevity OneSkin is powered by the breakthrough peptide OS-01, the first ingredient proven to reduce skin's biological age. I use the OS-01 Face and Eye formulas daily—they've transformed my skin's smoothness, firmness, and glow. Visit oneskin.co/VANESSA and use code VANESSA for 15% off your first purchase. NEW! Free High-Protein Keto Guide  Get delicious high protein meal recipes! Connect with Vanessa on Instagram @ketogenicgirl Get 25% off the Tone Device to try on a PSMF Day! Shop the collection HERE and use the code HOLIDAY25 Get 25% off the Tone LUX Crystal Red Light Therapy collection including the Crystal Mask and accessories the with the code HOLIDAY25 HERE Follow @optimalproteinpodcast on Instagram to see visuals and posts mentioned on this podcast. Link to join the Facebook group for the podcast The content provided in this podcast is for informational purposes only and should not be construed as medical advice. Consult with a healthcare professional before making significant changes to your diet or exercise regimen.

This week, I coached women who went from devastated to empowered in days, not months. Women who thought they needed all the answers before taking action. Women who discovered that external validation was always internal all along. This episode is a compilation of the most powerful coaching insights from just ONE week inside the Get Over Your Ex program—proof that when you have the right method and support, transformation happens fast. If you've been wondering what's actually possible when you stop doing this alone, listen to this. The Get Over Your Ex - https://dorothyabjohnson.com/getoveryourex 

Drs. Herzberg and Yu continue their discussion on emerging clinical data presented at ESMO and WCLC 2025. They highlight recent advancements in HER2-targeted therapies for NSCLC and review new HER2-targeted therapies, international study results, and the promise of evolving targeted approaches for HER2-altered lung cancer.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some fascinating breakthroughs and regulatory updates that are shaping the future of healthcare.Starting with a pivotal advancement in Alzheimer's research, a new drug has shown promising results in slowing cognitive decline in patients with early-stage Alzheimer's disease. This innovative therapy targets amyloid plaques in the brain, which are believed to play a central role in the progression of Alzheimer's. Recent clinical trials have demonstrated that patients receiving this treatment experienced a significant reduction in the rate of cognitive deterioration compared to those on a placebo. The implications of this development are profound, offering hope for millions affected by this debilitating condition. As researchers continue to unravel the mysteries of Alzheimer's, this breakthrough marks a crucial step forward in understanding and potentially halting disease progression.Moving on to regulatory news, the FDA has recently granted accelerated approval to a novel gene therapy for a rare genetic disorder known as spinal muscular atrophy (SMA). This condition, which affects motor neurons and leads to muscle wasting and weakness, primarily impacts infants and young children. The newly approved therapy works by delivering a functional copy of the defective gene directly into the patient's cells. Early trials have shown remarkable improvements in motor function and survival rates among treated infants. This approval represents not only a lifeline for affected families but also underscores the growing potential of gene therapies to address previously untreatable genetic diseases.In another significant development, researchers have unveiled a groundbreaking study on an experimental cancer vaccine that has demonstrated efficacy in preventing tumor growth in preclinical models. Unlike traditional vaccines aimed at infectious diseases, this cancer vaccine is designed to harness the body's immune system to specifically target and destroy cancer cells. The study's results indicate that the vaccine was successful in generating a robust immune response, which significantly inhibited tumor progression. If these findings can be replicated in human trials, it could open new avenues for cancer prevention and treatment, particularly for cancers with limited therapeutic options.Shifting our focus to trends within the industry, there's an increasing emphasis on personalized medicine, reflecting a broader shift towards treatments tailored to individual patients' genetic profiles. This approach aims to optimize therapeutic efficacy while minimizing adverse effects by considering each patient's unique genetic makeup. Advances in genomic sequencing technologies and bioinformatics are driving this transformation, enabling more precise diagnostics and targeted therapies. As personalized medicine continues to evolve, it holds the promise of revolutionizing how diseases are treated and managed in clinical practice.On the topic of drug approvals, a new oral medication for type 2 diabetes has received regulatory clearance after demonstrating superior glycemic control compared to existing treatments. This drug belongs to a novel class of medications that enhance insulin sensitivity and reduce glucose production by targeting specific metabolic pathways. Clinical trials indicated significant improvements in blood sugar levels and overall metabolic health among participants. Given the global prevalence of type 2 diabetes and its associated health complications, such advancements are crucial for improving patient outcomes and reducing healthcare burdens.Lastly, focusing on collaborations within the industry, several prominent pharmaceutical companies have announced partnerships aimed at accelerating research in infectious diseases.Support the show

Streamlined wish lists, clear goals, and priorities are the fuel for the most amazing breakthroughs. If you want to bypass the common source of self-sabotage-- being scattered and overwhelmed-- try this simple exercise to declutter your goals and plans! Sign up HERE to start the FREE New Year Decluttering Workshop and get an introduction to Beyond Decluttering, the life-changing new Feng Shui Decluttering Certification that will free you to zoom forward in your life: https://www.fengshuimagical.com/the_professional_decluttering_workshop  

Happy holidays from Sinica! This week, I speak with Paul Triolo, Senior Vice President for China and Technology Policy Lead at DGA Albright Stonebridge Group and nonresident honorary senior fellow on technology at the Asia Society Policy Institute's Center for China Analysis. On December 8th, Donald Trump announced via Truth Social that he would approve Nvidia H200 sales to vetted Chinese customers — a decision that immediately sparked fierce debate. Paul and I unpack why this decision was made, why it's provoked such strong reactions, and what it tells us about the future of technology export controls on China. We discuss the evolution of U.S. chip controls from the Entity List expansions under Trump's first term through the October 2022 rules and the Sullivan Doctrine, the role of David Sacks and Jensen Huang in advocating for this policy shift, whether Chinese firms will actually want to buy H200s given their heterogeneous hardware stacks and Beijing's autarky ambitions, what the Reuters report about China cracking ASML's EUV lithography code tells us about the choke point strategy, and whether selective engagement actually strengthens Taiwan's Silicon Shield or undermines it. This conversation is essential listening for understanding the strategic, technical, and political dimensions of the semiconductor competition.6:44 – What the H200 decision actually changes in the real world 9:23 – The evolution of U.S. chip controls: from Entity Lists to the Sullivan Doctrine 18:28 – How Jensen Huang and David Sacks convinced Trump 25:21 – The good-faith case for why export control advocates see H200 approval as a strategic mistake 32:12 – What H200s practically enable: training, inference, or stabilizing existing clusters 38:49 – Will Chinese companies actually buy H200s? The heterogeneous hardware reality 46:06 – The strategic contradiction: exporting 5nm GPUs while freezing tool controls at 16/14nm 51:01 – The Reuters EUV report and what it reveals about choke point technologies 58:43 – How Taiwan fits into this: does selective engagement strengthen the Silicon Shield? 1:07:26 – Looking ahead: broader rethinking of export controls or patchwork exceptions? 1:12:49 – What would have to be true in 2-3 years for critics to have been right about H200?Paying it forward: Poe Zhao and his Substack Hello China TechRecommendations: Paul: Zbig: The Life of Zbigniew Brzezinski, Amerca's Great Power Propheti by Ed Luce; Hyperdimensional Substack by Dean Ball Kaiser: Everything Is Tuberculosis by John Green; The Anthropocene Reviewed by John Green; So Very Small by Thomas LevensonSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Drs. Herzberg and Yu explore emerging clinical data from the 2025 meetings of the European Society For Medical Oncology (ESMO) and World Conference on Lung Cancer (WCLC), highlighting recent advancements in HER2-targeted therapies for NSCLC. Their discussion focuses on new drugs (eg, zongertinib and trastuzumab deruxtecan), their efficacy and safety profiles, and the potential for treating HER2 mutations and overexpression.

The future of apparel decorating is moving fast and if you're not ahead of the trends, your business could be playing catch-up. In this episode, we break down the must-watch innovations, hottest techniques, and game-changing products set to dominate 2026. From heat printing breakthroughs to design trends your customers will crave, we're giving you the insider scoop that others won't.Tune in because the trends wait for no one. Are you ready to lead, or will you follow?Connect with STAHLS':FacebookHeat Press for Profit Facebook GroupInstagramYouTubeTikTokLinkedin

2025 is coming to an end and Andrea and Taleesa are taking a look at what they've learned this past year as business owners in this fun episode. Join Andrea and Taleesa as they share some of the lessons they've learned from 2025, chat about new ways to grow your business while prioritizing what's important, and give you real-life tips to make 2026 your best year yet!If you enjoyed this episode please share, rate and review it! Also mentioned in today's episode: Recognizing what projects will bring you ROI 8:06Why you should be celebrating small wins 13:23Staying organized and focused with weekly meetings 17:30Creating better boundaries 25:18Links:Estie Social Suite:https://smithandcrawford.com/aesthetically-social-suite2026 Visibility Vault:https://smithandcrawford.com/visibility-vaultBenable List: https://benable.com/smithandcrawford/medspa-must-haves-little-luxuries-that-make-a-big-differenceShow transcripts: https://smithandcrawford.com/notesEmail us: hello@smithandcrawford.comJoin our newsletter: https://smithandcrawford.com/newsletterhttps://calendly.com/smithandcrawford/30-min-strategy-session?back=1&month=2024-10https://calendly.com/smithandcrawford/aesthetically-discovery-call?back=1&month=2024-08https://smithandcrawford.com/

What does it mean when 6,000 women a day enter menopause but there are only 4,100 certified clinicians to treat them?In this year end solo episode, I'm reflecting on 2025 in women's health. It was a year that felt heavy at the start personally for me after losing my mother, and globally with so much suffering and injustice. But even in all of that, women's health moved forward in meaningful ways. Not perfectly. Not fast enough. But enough that it deserves reflection.I'm covering the moments that shifted conversations this year from the FDA removing the black box warning on estrogen to new cervical cancer screening guidelines allowing self-collection HPV tests. From Addyi finally being approved for women under 65 to the release of comprehensive GSM guidelines that make genitourinary syndrome everyone's business, not just gynecologists'.And I'm getting personal about why I launched a concierge practice this year, what it taught me about the broken healthcare system, and why sexual health cannot be practiced in 10-minute appointments.Highlights:Why you're not too old for screening and what "safe exit criteria" really means.Menopause certification jumped from under 1,000 to over 4,100 practitioners in 2025.Menopause divorce vs. midlife clarity: Why hormonal chaos shouldn't decide your marriage.DARE to PLAY is a new, topical sildenafil launching in 2026 for female arousal disorder.Treating male partners reduces recurrent BV by 50% (New England Journal of Medicine).Hormone therapy for prevention: The nuanced conversation about bone health and cardiovascular risk.Why I launched a concierge practice and what it revealed about what women actually need.Thank you for being here for another year of Gyno Girl Presents: Sex, Drugs & Hormones. Your support, your messages, and your stories are what keep me going you are my why. If this year-in-review resonated with you, please share it with someone who needs to hear that they're not broken, not dramatic, and not asking for too much. And keep following the show in 2026 we've got incredible conversations lined up.Get in Touch with Me: WebsiteInstagramYoutubeSubstack

Tim McConnehey is the Founder and CEO of Izzard Inc., one of the fastest-growing publishing firms in America. A Harvard-trained AI strategist and alum of the Goldman Sachs 10,000 Small Businesses Program, he helps entrepreneurs scale smarter through AI-powered creative and operational transformation. Top 3 Value Bombs 1. AI elevates human creativity by enhancing and not replacing the emotional, structural, and strategic sides of storytelling. 2. Process clarity is the secret weapon of small business owners who want AI to meaningfully improve profit and performance. 3. Smart experimentation beats perfectionism every time; test, tweak, improve, repeat. Check out Tim's website to explore AI-powered publishing services, manuscript assessments, and author support - Izzard Ink Publishing Sponsors HighLevel - The ultimate all-in-one platform for entrepreneurs, marketers, coaches, and agencies. Learn more at HighLevelFire.com. Freedom Circle - A powerful community of entrepreneurs led by JLD. Are you ready to go from idea to income in 90-days? Visit Freedom-Circle.com to learn more.

If you've been hearing more about psychedelic therapy and wondering whether it's a genuine breakthrough for healing—or just the latest mental health trend—you're not alone. Many people feel curious, hopeful, and skeptical all at once. This conversation is meant to help you slow down, understand what the research actually shows, and think clearly about whether this path is right for you. In this episode of Love, Happiness and Success, I'm joined by psychiatrist and MDMA-assisted psychotherapist Dr. Scott Shannon, founder of Wholeness Center, the largest integrative mental health center in the U.S. Together, we talk about how psychedelic therapy works differently from conventional psychiatric treatment, why it can help disrupt rigid trauma patterns in the brain, and what researchers are learning about long-term healing—not just short-term symptom relief. We also spend time on the parts of this conversation that matter just as much: the risks, the ethical boundaries, and the importance of preparation, professional support, and integration. Psychedelic therapy isn't appropriate for everyone, and it isn't something to pursue casually or without careful guidance. This episode offers a grounded, responsible look at how people can think critically about safety, readiness, and what to look for in a qualified provider. As you listen, I invite you to reflect on a few questions: What kind of healing are you actually looking for? What does feeling “better” really mean to you? And how do you decide which growth paths deserve your trust, time, and care? Episode Breakdown: 00:00 Psychedelic therapy explained: promise, research, and real risks 02:31 Why psychedelic therapy differs from traditional psychiatric medication 04:55 Trauma, brain patterns, and how psychedelic therapy disrupts stuck loops 07:00 MDMA-assisted therapy for PTSD and why healing can continue long after treatment 12:21 A paradigm shift in mental health: supporting the brain's capacity to heal 19:30 What MDMA actually does in therapy: safety, self-compassion, and trauma processing 25:47 Mystical experience, meaning, and the spiritual dimension of psychedelic therapy 30:09 Ethical concerns, safety risks, and how to evaluate psychedelic therapy providers 38:00 Preparation and integration: why psychedelic therapy is more than the experience itself If this conversation leaves you thinking about your own healing or growth, I want to be clear that Growing Self does not offer psychedelic therapy. What we do offer is thoughtful, evidence-based therapy and coaching for people who want to grow with intention and care. If you'd like, I'd love to help you think through what kind of support would actually be most helpful for you. I've created a simple, private way to do that. By answering just a few quick questions, we can help match you with the right therapist or coach for a complimentary consultation—someone who understands what you're navigating and where you'd like to go next. Schedule a free consultation today. Consider it a small gift from me, and a gentle next step if you're ready for one. xoxo, Dr. Lisa Marie BobbyGrowing Self

Let us know how you enjoyed this episode!Most couples don't struggle because they don't love each other. They struggle because they were never taught how to communicate, regulate, and stay connected under stress.As I close out the year, I wanted to give you a gift. Instead of another tip or hack, I'm sharing the patterns and lessons I saw come up again and again in my client sessions this year.These are lessons learned in the midst of busy lives and chances are, you'll recognize yourself in at least one of them.In this episode, I break down six of the biggest takeaways that helped my clients transform their marriage in 2025.If you feel stuck in the same cycles or unsure what to focus on next in your marriage, this episode will help you zoom out, reflect, and choose a more intentional path forward.Resources mentioned:Download the Marriage 360 Review to gain clarity on what areas to focus on in your marriageBook a Clarity Call if you want support for your marriageThanks for listening!Connect and send a message letting me know what you took away from this episode: @michellepurtacoaching and follow me on threads @michellepurtacoaching!If you would like to support this show, please rate and review the show, and share it with people you know would love this show too!Additional Resources:Ready to put a stop to the arguments in your marriage?  Watch this free masterclass - The #1 Conversation Married Couples Need To Have (But Aren't)Want to handle conflict with more confidence? Download this free workbook!Wanna make communication feel easy and stop feeling like roommates so you can bring back the romance and excitement into your marriage? Learn more about how coaching here!Support the show

The King Was Born in a Place Nobody Expected—So Are Your Breakthrough is the topic that will be discussed today on RIOT Podcast, a Christian Discipleship Podcast.

A Christmas Day Special Celebrating the Insights, Breakthroughs, and Bold Conversations That Defined Our SeasonWelcome to this very special Christmas Day edition of the Affiliate Marketing Podcast. Throughout Season 23, we dug deep into the engines behind impactful content, questioned the role of SEO and AI algorithms in a world that still craves human connection, and spotlighted the evolution of affiliate marketing from community-driven growth to loyalty-first strategies and consumer discovery beyond the usual channels. Today's episode is a moment to look back on all we shared this season, appreciate how far we've come together, and celebrate the insights we gathered along the way. Grab a cup of something warm, settle in, and enjoy this Christmas Day Special as we wind up the season that's past and get ready for an even bigger one ahead.What You'll Hear in This Episode:The 6:1 content ratio that's reshaping digital marketing as Saurabh Singh reveals why educational content consistently outperforms promotional posts and how trust has become the new currency in affiliate marketingWhy most affiliate programs stall before they ever hit momentum with Florin Simovici's operational insights from 15 years of hands-on experience building scalable, sustainable programsThe harsh reality of building a content-first publisher from scratch as George Sullivan opens up about facing rejection after rejection and what affiliate managers misunderstand about the publisher's journeyWhy user-generated content is now the most powerful lever in affiliate growth from Dennis Yu's billion-dollar ad spend experience with brands like Nike and StarbucksHow AI-powered answer engines are capturing a quarter of global queries and what Colin Jeavons says this disruption really means for affiliate managers navigating an uncertain futureThe loyalty-building principles that turn silent affiliates into thriving communities as Alex Hitt shares why genuine connection, not higher commissions, truly drives retentionWhy most organisations stall on AI adoption with Katie King's roadmap for building strategic frameworks and embedding responsible governance before regulation arrivesHow daily payouts became the most powerful micro trust signal as the Exness team reveals their journey scaling from 18 to more than 100 countries with human-centric logicWhy platforms like Reddit are suddenly outranking traditional reviews and how Ewen Finser steered more than 100 websites through Google's volatility into the AI-driven landscapeHow to run your affiliate program ethically in the age of AI as Leanna Klyne and Lee-Ann discuss automation that stays human and what regulation might mean for your partner management.Call to ActionSeason 23 gave you the frameworks, now it's time to implement them. Whether you're rebuilding your onboarding process using Alex's white-glove approach, restructuring your content strategy around Saurabh's 6:1 ratio, or preparing your team for AI adoption using Katie's governance roadmap, the insights from this season only create value when you put them into action. Subscribe to the Affiliate Marketing Podcast so you're ready when Season 24 launches on New Year's Day with bold predictions for 2026 and conversations that push the boundaries of where affiliate and performance marketing are headed. DM Lee-Ann on LinkedIn and share what you're struggling with or want to know more about, and she'll find the right expert to get on the mic and talk us through it.Send me a text with your questions

How do you elevate your love life?Meet Anil Gupta - the Love Doctor!Anil is a world expert on relationships. He is the CEO of Love and the Breakthroughs that make it possible.He has helped singles and couples overcome the daily struggles and challenges to allow them to live very successful and fulfilled lives.He has performed his relationship and mindset workshops in over 18 countries and translated in 8 languages, with audiences of over 10,000. Anil "The Love Doctor" Gupta is a favorite speaker at every event he speaks at. He is the author of best selling book "Immediate Happiness". And is the Relationship Coach the Rich and Famous turn to for finding their true love, rebuilding parent child relationships, and transforming existing relationships to pure bliss.Listen as Anil shares:- how to achieve a richer, fuller, happier life- creating the love you desire in your life- recognising your worth- what behavioural patterns tell you- data collection during the dating stage- the 3 Gs of happiness- the requirements for a successful relationship- why so many do not succeed in relationships...and so much more!Connect with Anil:Website: https://meetanil.com/Additional Resources:FREE "Finding Love" e-book by Anil Gupta"Immediate Happiness" by Anil Gupta on Amazon"The Heart Map for Vitality" by Anil Gupta on AmazonListen to the Podcast, subscribe, leave a rating and a review:Apple: https://podcasts.apple.com/us/podcast/how-to-have-a-successful-relationship-the/id1614151066?i=1000742600303Spotify: https://open.spotify.com/episode/7jTpIF9fP9FPeBOt5fYAdN?si=yeQ_FAUQRNiM-_QxX2L1wghttps://open.spotify.com/episode/7jTpIF9fP9FPeBOt5fYAdNYouTube: https://youtu.be/wUn8hDqt8bk

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the significant events of 2025, a year marked by pivotal scientific breakthroughs, regulatory changes, and industry trends that have reshaped drug development and patient care.One of the standout advancements was Novo Nordisk gaining FDA approval for an oral version of Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist for obesity management. This marks a notable shift in treatment accessibility, as it provides an easier alternative to injectables for those managing weight and cardiovascular risks. This development could significantly enhance patient adherence and broaden access to this critical therapy.However, not all news was positive. Pfizer faced a challenging situation when a patient death occurred in the extension of their Hympavzi hemophilia study. Such incidents highlight the intrinsic risks of clinical trials, especially within gene therapy realms where safety monitoring is paramount. These events remind us of the delicate balance between innovation and patient safety in advanced biologic therapies.In legal news, Johnson & Johnson was ordered by a Baltimore jury to pay $1.56 billion in a talc-related cancer case. This ruling underscores heightened scrutiny on product safety and consumer protection within the pharmaceutical industry, potentially influencing future litigation and regulatory measures.Clinical trial outcomes also presented mixed results. Neurocrine Biosciences' Ingrezza did not meet efficacy endpoints in its phase 3 trial for cerebral palsy-related dyskinesia. Although it is approved for other movement disorders, this setback reflects the complexities involved in expanding drug indications. Such challenges highlight ongoing hurdles in translating preclinical successes into clinical realities.Despite geopolitical tensions, particularly between China and the U.S., Chinese biotech firms thrived, maintaining robust deal activity. China's continued growth as an innovation hub is driven by strategic investments and collaborations that bolster global drug development efforts, underscoring its increasing influence in life sciences.Regulatory landscapes also shifted with proposals from the Center for Medicare & Medicaid Innovation to align U.S. drug prices with international rates under Medicare Parts B and D. These proposed models could significantly impact pricing strategies and market dynamics within the U.S., requiring pharmaceutical companies to adapt while ensuring equitable access to medications.Ethical challenges surfaced as six individuals were charged with insider trading involving biotech stocks. Such incidents highlight the necessity for stringent ethical standards and regulatory oversight to maintain investor confidence and market integrity.Meanwhile, AstraZeneca's extended partnership with Niowave for actinium-225 supply reflects an interest in radiopharmaceuticals as targeted cancer therapies. This collaboration highlights the potential of radiopharmaceuticals in oncology, opening promising avenues for precision medicine approaches.As 2025 closes, it's clear that this year has been one of both triumphs and trials for the pharmaceutical and biotech industries. Scientific innovations like Novo Nordisk's oral GLP-1 receptor agonist offer new hope for patients, yet challenges such as clinical trial setbacks and legal battles indicate ongoing hurdles in drug development and commercialization. These developments will likely influence industry strategies and regulatory policies as we advance into 2026.The sustained momentum of China's biotech industry amid global trade tensions remains notable. This trend reflects China's strategic investments in biotech capabilities and its growing role in global markets despite geopolitical frictions.In clinical research, Hope BioscienceSupport the show

Watch the full episode with Steve Judd here: https://youtu.be/cKniikzZF2wSupport this show http://supporter.acast.com/inspiredevolution. Hosted on Acast. See acast.com/privacy for more information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.In a dynamic landscape marked by both advancements and challenges, the pharmaceutical and biotech sectors continue to evolve with notable scientific, regulatory, and strategic updates. Ipsen's recent $1 billion acquisition of Simcere's preclinical LRRC15-targeting asset underscores a growing focus on antibody-drug conjugates (ADCs). These conjugates leverage the targeted action of antibodies combined with the cytotoxic effects of drugs, representing a promising approach to cancer treatment by potentially minimizing systemic toxicity. Ipsen's strategic move reflects its commitment to expanding its oncology portfolio and staying competitive within the rapidly advancing ADC landscape.AstraZeneca has been active in its pursuit of innovative cancer treatments. The company has invested $100 million in Jacobio's clinical-stage pan-KRAS inhibitor, a promising development targeting KRAS mutations prevalent in various cancers. This investment aligns with AstraZeneca's strategy to tackle challenging oncogenic targets. However, their efforts faced a setback as their Phase 3 trial for ceralasertib, an ATR inhibitor for lung cancer, failed to meet its primary endpoint. Despite this setback, AstraZeneca maintains confidence by investing significantly in promising areas like KRAS inhibitors, highlighting the inherent risks involved in pioneering novel therapeutic strategies, particularly those aiming to overcome resistance mechanisms in immuno-oncology.BioMarin has quietly discontinued its liver disease candidate amid a $4.8 billion deal with Amicus. This decision points to the complex nature of pipeline prioritization and resource allocation within high-stakes financial environments. The company's strategic shifts reflect ongoing evaluations of their development priorities in light of evolving market demands.Boehringer Ingelheim has demonstrated a commitment to renal therapeutics with a $448 million investment in Rectify Pharmaceuticals for a preclinical chronic kidney disease program. This partnership seeks to address significant unmet medical needs within kidney disease treatment. Meanwhile, Gilead Sciences has entered into a $35 million licensing agreement with Assembly Biosciences for herpes simplex virus (HSV) assets, diversifying its infectious disease portfolio and expanding its reach within antiviral therapies.Novo Holdings-backed Windward Bio's acquisition of rights to Qyun's clinical-stage immunology bispecifics for $700 million highlights robust activity in the immunology space. Bispecific antibodies are gaining traction due to their ability to target two antigens simultaneously, offering enhanced therapeutic efficacy. This acquisition illustrates ongoing interest in this area as companies seek innovative solutions to complex immunological challenges.The broader industry is also witnessing strategic partnerships such as Aditum Bio's launch of a new biotech venture with Fosun Pharma. This collaboration aims to foster novel therapies through a synergistic blend of biotechnology innovation and pharmaceutical expertise. These alliances reflect an industry trend towards collaborative efforts that leverage diverse strengths to advance therapeutic development.In regulatory news, nine major pharmaceutical companies have reached agreements with the U.S. government to lower certain drug prices in exchange for tariff relief. This development signals ongoing negotiations aimed at balancing drug affordability with industry sustainability amid growing scrutiny over pricing practices.In December 2025, significant developments emerged, impacting scientific innovation, regulatory approvals, mergers, and strategic partnerships across the industry. Notably, the U.S. Food and Drug Administration (FDA) granted early approval to Cytokinetics' MyqorzSupport the show

This episode is for the woman who's been holding it all together, stuffing everything down, and convincing herself she doesn't have time, space, or safety to break down. Maybe you think breaking down is weakness, failure, or bad energy for your manifestations. Spoiler: none of that is true.We talk about why emotional breakdowns are actually a catalyst for breakthroughs, how bottling everything up blocks expansion, why sitting in emotions is different than actually moving them, and how safety, co-regulation, and nervous system capacity change everything.You'll learn how to let go in a way that creates space, not chaos and why releasing emotions helps you reset your nervous system, expand your window of tolerance, access deeper healing, and move forward without emotional hangovers.If you're tired of being “the strong one” all the time and you're ready to break down without breaking apart, this episode is for you.Join Club Becoming here.----------Welcome to Magnetic As F*ck, the podcast where personal development, mindset mastery, and spiritual awakening collide to help you become the most magnetic version of yourself. I'm your host, Mari Leigh, trauma practitioner, quantum energy & somatic healer, embodiment coach, and Akashic Record reader, dedicated to guiding women on their journey to healing, growth, and empowerment.In each episode, we dive deep into topics that resonate with the modern woman seeking transformation. From overcoming self-sabotage and navigating relationships to unlocking abundance and embracing spirituality, we explore it all. Whether you're looking to shed limiting beliefs, embody your next-level self, or connect with your soul's purpose, this podcast is your go-to resource for inspiration, insight, and practical tools.Join me as we peel back the layers, challenge the status quo, and embrace the journey of personal evolution together. It's time to feel free, confident, and utterly magnetic in every aspect of your life. Tune in to Magnetic As F*ck and let's create the life of your dreams, one episode at a time. Make sure to follow along & find more ways we can work together at ⁠⁠⁠⁠⁠⁠⁠⁠⁠marileigh.com⁠⁠⁠⁠⁠⁠⁠⁠⁠.⁠⁠⁠⁠⁠⁠⁠⁠⁠instagram.com/marileighb ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠instagram.com/magneticasfckpodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠tiktok.com/@marileighb⁠⁠⁠⁠⁠

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In the ever-evolving landscape of pharmaceuticals and biotechnology, a series of strategic transactions and scientific advancements are reshaping the industry.BioMarin's acquisition of Amicus Therapeutics for $4.8 billion is a significant highlight, marking the company's largest transaction to date. This move signifies a strategic pivot towards enhancing its capabilities in the rare disease sector, leveraging Amicus's expertise and robust pipeline to potentially improve patient outcomes in this highly specialized area. This acquisition is expected to enrich BioMarin's portfolio significantly with promising assets from Amicus, reflecting a strategic shift under new leadership towards rare disease treatments.Regulatory affairs have seen considerable activity as well, with the FDA raising concerns over manufacturing practices at Catalent's gene therapy facility. These issues, documented in a Form 483 following inspections, particularly pertain to the production of Elevidys. Such regulatory scrutiny emphasizes the critical importance of maintaining compliance with manufacturing standards in gene therapy—a burgeoning field within biotech that holds immense promise for treating genetically-driven conditions.The FDA's oversight extends beyond manufacturing practices to advertising, as evidenced by an untitled letter issued to Bristol Myers Squibb regarding their Cobenfy TV ad. This action is part of the FDA's broader initiative to ensure that direct-to-consumer marketing materials accurately portray drug benefits and risks, thereby protecting public health.In another strategic move, Alvotech and Teva are gearing up for the 2026 U.S. launch of an Eylea biosimilar following a settlement with Regeneron. This development highlights the competitive dynamics within the biosimilar market—a segment poised for growth as patents on major biologics expire, offering more cost-effective alternatives and expanding treatment access.Meanwhile, Clovis Oncology has achieved a milestone with Rubraca, which transitioned from accelerated approval to full FDA endorsement for prostate cancer treatment after five years. This progression underscores Rubraca's demonstrated efficacy and safety profile in addressing advanced prostate cancer—a notable achievement amid an increasingly competitive oncology market.Policy changes proposed by Health and Human Services Secretary Robert F. Kennedy Jr. could have profound implications by disrupting funding streams for hospitals providing gender-affirming care to minors. The potential impact on healthcare providers and patients who rely on these services is significant.Turning to clinical trials, Daiichi Sankyo has seen success with Enhertu receiving FDA approval for first-line HER2-positive breast cancer treatment. Nonetheless, challenges persist as a separate phase 3 trial for another antibody-drug conjugate was paused due to unexpected patient deaths. Meanwhile, Takeda plans to seek FDA approval for its TYK2 inhibitor following successful phase 3 trials in psoriasis—indicating promising potential in autoimmune disease therapies.Strategic shifts are evident across organizations as well, highlighted by Kathy Fernando's departure from Pfizer to join Replicate Bioscience as Chief Business Officer. Her new role focuses on advancing Replicate's self-replicating RNA technology platform—an area gaining traction due to its implications for vaccine development and therapeutic applications.On the clinical trials front, Altimmune reported encouraging results from a 48-week study on metabolic dysfunction-associated steatohepatitis (MASH). Their GLP-1/glucagon dual receptor agonist demonstrated sustained weight loss and improvements in non-invasive liver fibrosis measures—offering new hope for MASH patients who face limited treSupport the show

Host Piya Chattopadhyay speaks with The Atlantic's Toluse "Tolu" Olorunnipa and Politico's Hailey Fuchs about the revelations in Friday's partial release of the Epstein files – and how they intersect with U.S. politics, baker and writer Ruby Tandoh explains how virality shapes our appetites, Dr. Siddhartha Mukherjee discusses breakthroughs in cancer research, and novelist Gary Shteyngart explores the parallels between his dystopian new novel and life in the U.S. today.

In this episode of The AI Report, your always-on AI anchors Artie Intel and Micheline Learning break down December 2025’s wildest developments in artificial intelligence, from the latest “singularity-speed” model launches to the hot new tools quietly rewiring how humans work, create, and build businesses. They unpack the new generation of frontier models such as Claude Opus 4.5, Gemini 3, and GPT‑5.2, and explain why everyone from solo creators to Fortune 500 companies is racing to plug them into real workflows rather than just playing with demos.​ You’ll hear how AI is now helping inspect semiconductor chips with near‑perfect accuracy, acting as an autonomous “AI scientist” to hunt for discoveries, and even critiquing its own math proofs so humans can trust the numbers. The show also tours the month’s hottest tools: Runway Gen‑4 Turbo for video, Notion AI 3.0 for workspace automation, Adobe Firefly 4 for image generation, and advanced coding copilots and observability platforms that are changing how software gets shipped.​ Artie and Micheline zoom out to tackle the significant tensions of 2025’s “AI hype correction”: running out of quality training data, the rise of synthetic data, and the gap between shiny pilots and real productivity gains in the AI economy. They examine how governments are responding, with significant investments such as the U.S. Department of Energy’s Genesis Mission for AI‑powered science, and what it all means for workers, creators, and decision‑makers trying to stay ahead of the algorithm.​ If you want one tight, fast‑moving briefing that covers model wars, new tools, scientific breakthroughs, and the real risks behind the headlines, this is your must‑hear download on the state of AI at the end of 2025.​ Sponsor: This episode of The AI Report is brought to you by Amazon.com, your always‑open destination for last‑minute gifts, from smart gadgets to everyday essentials, delivered at the speed of your next great idea.  

Strategy founder and executive chairman Michael Saylor named one of CoinDesk's 50 Most Influential. Strategy founder and executive chairman Michael Saylor was named one of CoinDesk's 50 Most Influential people of 2025. He reflects on the evolution of bitcoin treasuries, from a niche corporate experiment into a global phenomenon, detailing how Strategy has moved beyond simple accumulation into a high-growth operating business centered on digital credit. Plus, his bullish case for bitcoin's growth and outlook into the asset's volatility. – For more, check out CoinDesk's 50 Most Influential article on Michael Saylor: https://www.coindesk.com/business/2025/12/12/most-influential-michael-saylor.  To see the full list, visit: ⁠https://www.coindesk.com/most-influential-2025⁠.  – Timecodes:  01:21 Michael Saylor's Bitcoin Journey 02:52 Institutional Support and Bitcoin Volatility 04:18 Bitcoin Treasury Strategies and Digital Credit 06:03 Exploring Digital Credit and Its Practicality 11:49 The Future of Bitcoin Treasury Companies 12:42 Innovations in Digital Credit Instruments 27:08 Challenges and Breakthroughs in 2025 39:16 Looking Ahead: Bitcoin's Price and Market Structure Legislation 43:29 Top Digital Assets for 2026 - Break the cycle of exploitation. Break down the barriers to truth. Break into the next generation of privacy. Break Free. Free to scroll without being monetized. Free from censorship. Freedom without fear. We deserve more when it comes to privacy. Experience the next generation of blockchain that is private and inclusive by design. Break free with Midnight, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠midnight.network/break-free⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ - This episode was hosted by Jennifer Sanasie.

The 2025 NAIA Cross Country National Championships are in the books — and we're breaking it all down with the coaches who lived it.Originally streamed LIVE on YouTube on November 24, 2025, this episode is now available on all Airey Bros Radio podcast platforms as Episode 421.Recorded just days after the championship meet at Apalachee Regional Park in Tallahassee, Florida, the Airey Bros are joined by five elite NAIA head coaches to unpack team titles, podium finishes, All-American performances, heartbreak by a single point, and the moments you don't see on the results sheet.

Spiritual awakening in 2025 is changing fast. In this video, I share the top 5 spiritual lessons of 2025, including how AI can weaken intuition, why nervous system healing is essential for spiritual growth, and what it really means to trust your inner guidance during awakening.If you're experiencing a spiritual awakening, developing your intuition, or feeling overwhelmed by information, technology, or AI tools, these lessons will help you reconnect to your inner knowing in a grounded, embodied way.Sharing my top 5 Reality Check Breakthroughs I had this year. In 2025, my spiritual growth changed in ways I didn't expect... This year taught me that spiritual growth isn't linear — it's a spiral, intuition isn't something you “optimize,” and that over-reliance on AI and external guidance can quietly disconnect us from our inner knowing.In this video, I share the top 5 spiritual lessons I learned in 2025, including how intuition develops through nervous system regulation, why growth often reveals itself in strange ways, and how learning to feel safe with uncertainty is essential for spiritual awakening (and the collective chaos happening all around us) This isn't about rejecting technology — it's about discernment, embodiment, and reclaiming intuitive authority in a world that constantly pulls us outward.Lets be clear i'm not anti-AI but I SURE think it's doing something bts to our intuition if we're not careful and it's DESTROYING FREE THINKING. Let's talk about it.✨ In this video, you'll learn:Why spiritual growth happens in spirals, not straight linesHow intuition acts as your guiding post during awakeningThe hidden ways AI can suppress free thinking and intuition when used as a crutchWhy nervous system healing is foundational for intuitive developmentHow to feel safe walking with uncertainty instead of forcing answersIf you're navigating a spiritual awakening, emotional healing, intuition development, or feeling overwhelmed by information overload, this episode is for you.Before you go don't forget:

Aviation Week's James Pozzi, Lee Ann Shay, Lindsay Bjerregaard and Sean Broderick look back at 2025 and reflect on the biggest stories and breakthroughs in the MRO world. Is Parts Integrity Finally Having Its Moment? Supply Chain Integrity Coalition Shifts Gears  Rolls-Royce Unveils China MRO Joint Venture How Stability, Slots And Strategy Are Reshaping Base Maintenance Schools Say FAA Testing Hurdles Are Stifling MRO Workforce Growth

In this episode of The Brainy Business podcast, Melina Palmer speaks with Muriel Wilkins, author of Leadership Unblocked: The Beliefs That Limit Your Potential. Together, they delve into the often-hidden beliefs that can hinder effective leadership and personal growth. Muriel, an executive coach with over 20 years of experience, shares insights from her extensive work with C-suite leaders, revealing seven common beliefs that can create barriers to success. The conversation explores how these beliefs—such as "I need to be involved" and "I can't make a mistake"—shape our behaviors and decision-making processes. Muriel emphasizes the importance of self-awareness and shifting mindset to overcome these challenges, encouraging listeners to reflect on their own assumptions and the narratives they tell themselves. As you tune in, think about which beliefs may be holding you back and how you can reclaim your agency as a leader. In this episode: Discover the seven hidden beliefs that can limit leadership potential. Learn how to recognize the narratives that shape your experiences. Explore practical strategies for shifting mindset and overcoming barriers. Gain insights into the importance of external feedback and self-reflection. Understand how to take actionable steps toward personal and professional growth. Get important links, top recommended books and episodes, and a full transcript at thebrainybusiness.com/556. Looking to explore applications of behavioral economics further?  Learn With Us on our website. Subscribe to Melina's Newsletter, Brainy Bites.  Let's connect: Send Us a Message Follow Melina on LinkedIn The Brainy Business on YouTube The Brainy Business on Instagram

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, welcomes William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to explore recent news updates and key advancements shaping the industry in 2025.Staying healthy during the holidays (00:18): Discover how to protect yourself and others as a new influenza strain, holiday gatherings, and increased travel raise the risk of spreading viruses. 2025 breakthroughs and trends (04:31): Learn more about the technologies, regulations, and innovation influencing the future of clinical diagnostics. Note: Information in this post was accurate at the time of its posting.Resources"Answers From the Lab” podcast: Innovations Set to Shape the Industry in 2025Dr. Morice shares trends and predictions for 2025Mayo Clinic Minute: How to prepare for the influenza seasonMayo Clinic Minute: Wash your hands for better healthVaccines and viruses: Protecting health across generations

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to⁠ outcomesrocket.com Advances in AI are transforming both large-scale population analytics and ultra-precise, small-data insights that can guide individualized treatment. In this episode, Yves Lussier, Chair of Biomedical Informatics and Professor of Medicine, discusses the deep legacy of innovation behind modern electronic health records, the evolution of biomedical informatics, and the rise of AI techniques that extract meaning from both massive and minimal datasets. He explains how the “blessing of dimensionality” enables N-of-1 precision genomics, why counterfactual data and adversarial risks matter for large language models, and how engineered negative datasets could strengthen future AI systems. He also reflects on his entrepreneurial journey, from pioneering pen-based AI medical records in 1991 to building clinical data warehouses and founding major bioinformatics programs. Yves shares lessons on risk, career leaps, and the cultural ecosystems that fuel innovation.  Tune in and learn how cutting-edge informatics is reshaping research, care, and the future of AI-driven medicine! Resources: Connect with and follow Yves Lussier on LinkedIn. Follow the University of Utah School of Medicine on LinkedIn and visit their website!

Breakthroughs may look sudden, but nothing in God's kingdom happens by accident

Dr. Tina Kaczor and Dr. Leah Sherman discuss new diagnostic tools that can tell benign tumors from cancer in the pancreas, highlight the growing concerns over microplastics, and explore the link between ultra-processed foods and early colorectal cancer. They also highlight some amazing inventions by teenagers, like a melanoma-detection app and a skin-cancer-reducing soap. Last, they cover the benefits of hypnosis before breast cancer surgery and the health impact of commonly used chemicals in dry cleaning. This episode provides valuable insights for anyone interested in cancer prevention, early diagnosis, and overall wellness.Soap for skin cancers invented by TIME's Kid of the Year, Hemen BekeleA skin cancer detecting app invented by Richmond, VA high-schoolersThe dramatic increase in glyphosate use across the Midwest in the USAThe rising rates of cancer in young people around the worldExposure of rat fetuses to glyphosate levels led to early cancer developmentThe rising rate of glyphosate exposure over time Support the showBecome a member of The Cancer Pod Community! Gain access to live Q&As, exclusive content, and so much more! Join us today! Check out our website! Looking for more information? We have blogs, merch, and all of our episodes listed by season and category. Shop our favorite reads! We've joined with Bookshop.org to offer some of our fave books! Have a comment or suggestion? Email us at thecancerpod@gmail.com Follow us wherever you browse. We're always @TheCancerPod: Instagram Bluesky Facebook LinkedIn YouTube THANK YOU!!

Synopsis: This episode is proudly sponsored by Quartzy. Roivant Sciences CEO Matt Gline returns to Biotech 2050 for a deeply reflective conversation with host Rahul Chaturvedi on what it really takes to build a biotech company that lasts. From Roivant's transformational $7B Pfizer-to-Roche deal to delivering registrational Phase 3 data in dermatomyositis—one of biotech's most difficult graveyard indications—Matt shares how disciplined execution, decentralization, and learning from failure shaped Roivant's trajectory. The discussion explores Roivant's unique “Vant” model, why multiple CEOs can outperform centralized command-and-control structures, and how thoughtful clinical trial design—down to steroid tapering and site execution—can make or break outcomes in rare disease development. Beyond science and strategy, Matt reflects candidly on his own evolution as CEO, the realities of leading a public biotech through volatile markets, and why authenticity, focus, and embracing hard lessons matter more than chasing hype. This episode is a masterclass in biotech leadership, clinical development, and long-term value creation. Biography: Matt Gline serves as Chief Executive Officer of Roivant Sciences. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer. From April 2014 to March 2016, he was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, where he focused on technology and data strategy. Prior to Goldman Sachs, Mr. Gline was a co-founder of Fourthree, a risk analytics technology and consulting company. From 2008 to 2012, he served as Vice President at Barclays, Enterprise Risk Management Advisory, where he provided analysis for corporate clients related to capital markets access for financing and risk management. Mr. Gline earned his A.B. in Physics from Harvard College.

Earlier this year, The Michael J. Fox Foundation hosted its 2025 Research Roundtable, “Building on Breakthroughs.” Tune into audio from this event to hear Parkinson's experts and MJFF staff discuss the latest in lifestyle medicine and treatments in the pipeline, as well as the power of advocating for Parkinson's policy.Like our podcasts? Please consider leaving a rating or review and sharing the series with your community. https://apple.co/3p02Jw0Whether you have Parkinson's or not, you can help move research forward. Join the study that's changing everything at michaeljfox.org/podcast-ppmiMentioned in this episode:Research will move us closer to a cure for Parkinson's — but we can't do it without you. Help us accelerate more life-changing breakthroughs by visiting michaeljfox.org/givetoresearch to donate today.

What happens when four hard-charging leaders shut the door, turn on the mics, and tell the unfiltered truth about business, burnout, delegation, AI, hiring, and scaling? You get one of the rawest, most practical leadership episodes we've ever released. Host Sean Meyers is joined by the Level Up + Live leadership team, Cody Schneider, Micah Harhoff, and Michael David Riley (MD), for a no-fluff, high-impact roundtable Q&A straight from our members. They tackle the REAL questions every entrepreneur is scared to ask: The first bottleneck that forced them to stop working in the business and start working on it How they're using AI without killing culture or trust When to hire (even when you “can't afford it”) How much to REALLY spend on marketing The biggest mistakes owners make when scaling too fast… or too slow Why burnout, ego, and control quietly destroy businesses The truth about proving people wrong vs. finding real purpose You'll hear real stories about missed family moments, burnout, failed businesses, delegation struggles, buy-back-your-time strategies, leadership growth, and the systems that separate hustlers from true builders. This is not a theory. This is battle-tested leadership from the trenches. And just when the conversation hits full stride… they drop a cliffhanger and announce Part 2 is coming. If you're an entrepreneur, emerging leader, or business owner who's serious about building something that lasts, this episode will hit different. Press play. Take notes. Level Up. Live better. Ready to Level Up Your Life and Business? Join our Level Up + Live Mastermind, the weekly power room for business owners and leaders hungry for clarity, accountability, and growth without sacrificing their soul in the process. Try it FREE for one month, levelupandlive.com/contact Hit play. Get uncomfortable. Live with intention. Stay in the loop; stay in the lead! Get exclusive insights on business, fitness, leadership, and community straight to your inbox! Subscribe to the Level Up + Live newsletter now Level Up + Live  Tools to Level Up! Free Resources — Level Up + Live

Social Media⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Say hi on TikTok⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Say Hi on Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Email List⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----If you've been stuck, doubting your worth, or drowning in regret — this episode is your wake-up call. Henry Lawrence drops a fire-filled reminder that you are not your past. You're not the failures, the shame, or the missed chances. You are potential in motion.In this soul-shifting transmission from The Positive Mindset Podcast, you'll learn:How to break free from your history and step into your powerWhy one moment of clarity can define your legacyThe spiritual truth about pressure, transformation, and becoming the diamondA guided breathwork session to lock in your highest visionThe deeper reason you're still here — and why it's not too lateClose your eyes. Breathe in. See your future self.This is the day everything shifts.

The final Fed meeting of 2025 delivered a surprise rate cut, but the real story is how the market is reacting. In this week's Weekly Rollup, Ryan and David unpack what the new policy shift means for crypto liquidity, why regulators across the SEC, CFTC, and OCC are suddenly embracing onchain markets, and how Tom Lee's massive ETH accumulation is reshaping sentiment. We also get into Ethereum's growing momentum from ZK advancements and blob upgrades, the ZKsync Atlas rollout, Base's bridge drama with Solana, and Farcaster's pivot away from social. Plus, the rise of tokenization, new prediction market rails, and whether this week marks the first real cycle turn for Ethereum. ------

In today's episode of Every Day Is Saturday, Sam Crowley breaks down the life-changing power of “one more rep.” Whether you're in the gym, rebuilding your confidence, growing your faith, or fighting for a dream that feels out of reach, the breakthrough never comes from the first easy steps — it comes from the rep you don't want to do. The rep that burns. The rep no one sees. The rep that defines your character. Sam shares a raw, real story from his Wolverine comeback workout and explains why that final rep becomes the moment where your identity shifts and momentum returns. You'll learn how the “one more rep mindset” applies to fitness, business, relationships, and personal transformation — and why this simple discipline separates people who stay stuck from people who change their entire life. If you need motivation, clarity, or a push to get back on track, this episode will light a fire under you. Listen now and discover the small action that leads to massive breakthroughs.

From breakthrough AI diagnostics to personalized immunotherapy treatments, cancer care is undergoing a revolution that's already saving lives.Dr. Ross Levine, Chief Scientific Officer at Memorial Sloan Kettering, shares how new technologies are helping doctors detect cancer earlier, treat it more effectively, and transform what was once untreatable into manageable conditions. Whether you're navigating cancer personally or professionally, this conversation offers crucial insights into the future of medicine and why there's unprecedented hope in cancer treatment today.You can find Ross at: Website | Episode TranscriptIf you LOVED this episode, don't miss a single conversation in our Future of Medicine series, airing every Monday through December. Follow Good Life Project wherever you listen to podcasts to catch them all.Check out our offerings & partners: Join My New Writing Project: Awake at the WheelVisit Our Sponsor Page For Great Resources & Discount Codes Hosted on Acast. See acast.com/privacy for more information.

Bill rambles about breakthroughs, a bike ride, and the valley. (00:00) - Thursday Afternoon Podcast (30:35) - Thursday Afternoon Throwback 12-4-17 - Bill rambles about la-z-boys, college playoffs, and nosy neighbors. (01:54:06) - Anything Better Podcast - NFL Week 14 Preview with Paul Virzi. Bill went 3-1 and Paul went 2-2. They talk about the weeks games as well as crazy people in public, the scene in New Orleans, and Lane Kiffin's move. SimpliSafe: This month only, take 50% off any new system. This is one of the best prices you will ever see for SimpliSafe. Go to http://www.SimpliSafe.com/BURR Helix: Take the Helix Sleep Quiz and find your perfect mattress in under two minutes. Go to http://www.HelixSleep.com/burr for 20% off sitewide.